ECL-IAA and ECL-GADA Can Identify High-Risk Single Autoantibody-Positive Relatives in the TrialNet Pathway to Prevention Study.

ABSTRACT:

Background

Relatives with single positive islet autoantibodies have a much lower risk of progression to diabetes than those with multiple autoantibodies.

Materials and methods

TrialNet subjects positive for single autoantibody to insulin (mIAA) (n = 50) or single autoantibody to glutamic acid decarboxylase (GADA) (n = 50) were analyzed using new electrochemiluminescence (ECL) assays (ECL-IAA and ECL-GADA, respectively) at their initial visit and longitudinally over time. Affinity assays were performed on a subset of single autoantibody-positive subjects at initial and most recent visits.

Results

After a mean follow-up of 5.3 years, 20 subjects developed type 1 diabetes. Among either single GADA or single mIAA subjects, those who were positive in the ECL assay showed h

SUBMITTER: Steck AK 

PROVIDER: S-EPMC4931768 | biostudies-literature | 2016 Jul

REPOSITORIES: biostudies-literature